"Although ischemic optic neuropathy was rare, it is clinically important because it can involve sudden vision loss," said Chintan Dave, a core faculty member of the Center for Pharmacoepidemiology and Treatment Science at Rutgers Institute for Health, Health Care Policy and Aging Research. "The increase in risk was small — approximately three to four additional cases per 10,000 patients treated with GLP-1s over 18 months, but clinicians and patients should be aware of this potential association."

Takeaway: the signal is small in absolute terms but large enough to change what clinicians tell patients about warning symptoms.

Who may be most at risk?

Cases clustered among men and among adults in the older segment of the study population.

"Most patients in our study who had ischemic optic neuropathy were either men or men and women aged 50 to 65," said Dave, who is also an associate professor at the Ernest Mario School of Pharmacy and the study's lead author. "Because ischemic optic neuropathy can present with sudden vision loss, which may be permanent, early recognition of symptoms and prompt ophthalmologic evaluation may be especially important for patients at higher baseline risk."

More than 80% of ischemic optic neuropathy cases are estimated to involve the non-arteritic anterior form — insufficient blood supply to the front portion of the optic nerve. Patients usually notice sudden blurriness, dimming, or missing areas in the field of view of one eye, rather than complete blindness.

Recovery is limited. According to Dave, about one-third of affected patients regain some vision, usually within the first six months. Even then, some impairment typically remains.

Takeaway: men and patients aged 50 to 65 deserve the clearest guidance on recognizing sudden vision changes.

Do these drugs actually cause vision loss?

Not proven — and the researchers say so plainly. The study found an association, not causation. Differences in patients' underlying health conditions could explain part of the observed risk.

That limitation matters for anyone translating this finding into practice. Additional research will need to determine whether the medications themselves contribute to optic nerve damage.

For now, the practical message is symptom awareness: anyone taking a GLP-1 who experiences sudden vision changes should seek prompt medical evaluation, especially those already at elevated baseline risk.

The study's co-authors were Kamika Reynolds and Kimberly O'Malley of the Rutgers Institute for Health and Jason Roy of the Rutgers School of Public Health.

Rare risk, permanent consequence — that is the trade-off this study puts on clinicians' desks.